These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 10634132)
1. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Dalén P; Dahl ML; Eichelbaum M; Bertilsson L; Wilkinson GR Pharmacogenetics; 1999 Dec; 9(6):697-706. PubMed ID: 10634132 [TBL] [Abstract][Full Text] [Related]
2. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461 [TBL] [Abstract][Full Text] [Related]
3. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768 [TBL] [Abstract][Full Text] [Related]
4. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Dorado P; Berecz R; Cáceres MC; González I; Cobaleda J; Llerena A Clin Chem Lab Med; 2005; 43(3):275-9. PubMed ID: 15843230 [TBL] [Abstract][Full Text] [Related]
5. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134 [TBL] [Abstract][Full Text] [Related]
7. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Droll K; Bruce-Mensah K; Otton SV; Gaedigk A; Sellers EM; Tyndale RF Pharmacogenetics; 1998 Aug; 8(4):325-33. PubMed ID: 9731719 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. Dalén P; Dahl M; Andersson K; Bertilsson L Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914 [TBL] [Abstract][Full Text] [Related]
9. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874 [TBL] [Abstract][Full Text] [Related]
10. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Roh HK; Dahl ML; Johansson I; Ingelman-Sundberg M; Cha YN; Bertilsson L Pharmacogenetics; 1996 Oct; 6(5):441-7. PubMed ID: 8946476 [TBL] [Abstract][Full Text] [Related]
11. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes. Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167 [TBL] [Abstract][Full Text] [Related]
12. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177 [TBL] [Abstract][Full Text] [Related]
13. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Weerasuriya K; Jayakody RL; Smith CA; Wolf CR; Tucker GT; Lennard MS Br J Clin Pharmacol; 1994 Nov; 38(5):466-70. PubMed ID: 7893590 [TBL] [Abstract][Full Text] [Related]
14. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Scheinin H; Anttila M; Dahl ML; Karnani H; Nyman L; Taavitsainen P; Pelkonen O; Bertilsson L Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797 [TBL] [Abstract][Full Text] [Related]
15. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype. Wennerholm A; Johansson I; Massele AY; Lande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL Pharmacogenetics; 1999 Dec; 9(6):707-14. PubMed ID: 10634133 [TBL] [Abstract][Full Text] [Related]
16. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439 [TBL] [Abstract][Full Text] [Related]
17. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. LLerena A; Berecz R; de la Rubia A; Fernández-Salguero P; Dorado P Ther Drug Monit; 2001 Dec; 23(6):616-20. PubMed ID: 11802093 [TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989 [TBL] [Abstract][Full Text] [Related]